Showing results (401-410 of 412) with videos related to
Sort By:
Pageof 42
Circulation|March 21, 2020
Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial HypertensionFrançois Potus, Michael W Pauciulo, Elina K Cook, et al.Nature Cardiovascular Research|June 12, 2023
Blood flow modeling reveals improved collateral artery performance during the regenerative period in mammalian heartsSuhaas Anbazhakan, Pamela E Rios Coronado, Ana Natalia L Sy-Quia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.Acta Neuropathologica Communications|April 29, 2023
Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutationsSkylar E Davis, Anna K Cook, Justin A Hall, et al.Neurobiology of Disease|June 9, 2026
Human TDP-43 expression worsens FTD-related phenotypes in progranulin-insufficient miceAnna K Cook, Benjamin Lin, Yumo Song, et al.European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.Journal of Medicinal Chemistry|January 2, 2010
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.JAMA Network Open|October 5, 2023
Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical TrialsPaul A Harris, Sarah E Dunsmore, Jane C Atkinson, et al.Journal of Medicinal Chemistry|July 11, 2006
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationshipDonn G Wishka, Daniel P Walker, Karen M Yates, et al.Scientific Reports|October 16, 2023
Simultaneous bright- and dark-field X-ray microscopy at X-ray free electron lasersLeora E Dresselhaus-Marais, Bernard Kozioziemski, Theodor S Holstad, et al.Pageof 42